我们不是急诊医疗服务提供方紧急情况请立即联系当地急救服务
CAR-T therapy information

Understanding CAR-T Cell Therapy

Learn how CAR-T therapy works, which patients may be evaluated and how international case review can be coordinated.

Chinese cancer specialists reviewing PET-CT imaging with an international patient

What Is CAR-T?

CAR-T is a personalized cellular immunotherapy in which a patient’s T cells are collected, genetically modified to recognize a specific target and returned to the patient to attack certain cancer cells.

CAR-T is not appropriate for every cancer or every patient. Eligibility and treatment decisions require full medical evaluation by qualified physicians.

Conditions Commonly Evaluated

B-cell acute lymphoblastic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMantle cell lymphomaMultiple myelomaOther selected hematologic malignancies

Actual eligibility depends on diagnosis, disease subtype, biomarkers, prior treatment, overall health and physician evaluation.

Information for Eligibility Review

Confirmed diagnosisPathology reportFlow cytometryImmunohistochemistryMolecular testingBone marrow reportPET-CT, CT or MRIPrevious treatment historyMedication listRecent blood testsOrgan function assessmentCurrent disease status
Risks and considerations

CAR-T may involve serious and potentially life-threatening risks

Patients require assessment, preparation and close monitoring by an experienced medical team.

Cytokine release syndrome
Neurological toxicity
Infection risk
Low blood counts
Need for close monitoring
Possible hospitalization
Possibility of treatment failure or relapse
Important questions

CAR-T frequently asked questions

Is CAR-T suitable for all cancers?

No. CAR-T is used for selected conditions and is not appropriate for every cancer or patient.

How is eligibility assessed?

Physicians review the confirmed diagnosis, subtype, biomarkers, prior treatment, current disease status, organ function and overall health.

What medical records are required?

Pathology, imaging, laboratory and molecular results, bone marrow reports where relevant, treatment history and current medication are commonly requested.

How long does the process take?

Timing varies by evaluation, testing, hospital capacity, cell manufacturing and the patient’s condition. No fixed timeline can be promised.

Is hospitalization required?

Hospitalization and close monitoring may be required. The treating medical team determines the plan.

What are the possible risks?

Risks may include cytokine release syndrome, neurological toxicity, infection and low blood counts, among others.

Can international patients receive CAR-T in China?

Selected international patients may be evaluated. Hospital acceptance and treatment suitability are not guaranteed.

Does submitting a case guarantee acceptance?

No. Submission initiates coordination only and does not guarantee eligibility or acceptance.

Are treatment costs fixed?

No. Estimates depend on the case, hospital, testing, treatment course and complications.

What happens after returning home?

Follow-up planning and communication with local and treating teams may be coordinated.

CAR-T medical disclaimerCAR-T therapy is a complex medical treatment and may involve serious risks. Eligibility and treatment decisions must be made by qualified physicians after full medical evaluation. The information provided on this website is for general educational and informational purposes only. It does not constitute medical advice, diagnosis or treatment. All medical decisions must be made by qualified healthcare professionals after reviewing the patient’s individual condition.
China Medical Net is an international medical coordination service and is not a hospital, clinic or emergency medical provider. If you are experiencing a medical emergency, contact your local emergency services immediately.